Clinical Trial

The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study

Study acronym: STAR
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved. Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored.
Trial Details
NCT Number NCT06136949
Lead Sponsor Centro di Riferimento Oncologico - Aviano
Conditions Colorectal Cancer
Enrollment 150 participants
Start Date 2023-05-22
Primary Completion 2032-12-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-11-18